September 2026
All columns and Brief analyses.
10 results
RBI decision leaves Tata Sons under a public-listing mandate
The Reserve Bank of India rejected Tata Sons' request to surrender its core investment company registration. Business Today and ThePrint report that the decision leaves the holding company subject to the listing mandate for upper-layer non-bank finance companies; Tata Sons and the RBI had not commented when the reports appeared.
Risvutatug rezetecan lifted median survival from 10.3 to 18.5 months in relapsed small-cell lung cancer
In the phase 3 ARTEMIS-008 trial, presented in the opening Presidential Symposium of the World Conference on Lung Cancer in Seoul, the B7-H3-directed antibody-drug conjugate risvutatug rezetecan kept patients with relapsed small-cell lung cancer alive for a median 18.5 months against 10.3 months with the chemotherapy topotecan, a 54 percent lower risk of death. Response rates and progression-free survival also favoured the drug, and severe side effects were less frequent. Developer Hansoh Pharma has already filed for approval in China.
Roche presents TAISHAN-302 Tam-Peli results at WCLC 2026
A Roche release and an Endpoint Arena report match the TAISHAN-302 result as the same drug-development event dated 13 September. The sources say the Tam-Peli and topotecan comparison was presented at WCLC 2026. With no detailed scientific publication in the pool, the card stays with the announcement's identity, scope and publication status; it makes no clinical-effect or treatment recommendation.
Russian drone strikes Kyiv-Warsaw train 2 km from the border
Ukraine railway operator said a Russian drone struck the locomotive of a Kyiv-Warsaw passenger train in Volyn about 2 km from Poland. The crew received advance warning and no passengers were injured. A nearby petrol station and trucks were also damaged, while Poland activated its air defences during the wider attack but said its airspace was not violated.
Sacituzumab govitecan plus pembrolizumab missed both survival goals in EVOKE-03
Adding the antibody-drug conjugate sacituzumab govitecan to pembrolizumab did not significantly delay progression or extend life in untreated metastatic non-small cell lung cancer with high PD-L1 expression, the phase 3 EVOKE-03 trial reported at the World Conference on Lung Cancer in Seoul. Median progression-free survival was 11.8 months with the combination and 7.7 months with pembrolizumab alone, short of its statistical bar, and overall survival was 21.5 against 22.8 months. Responses were more frequent, and so were severe side effects.
Speaker Johnson gives no guarantee on Trump's 5,000 dollar dividend cheques
House Speaker Mike Johnson said the 5,000 dollar payment Donald Trump has tied to Republicans keeping their congressional majority in November's midterms needs approval from Congress, and he declined to guarantee it. On NBC's Meet the Press he committed only to Congress working through the idea and finding consensus. The programme's estimated cost is 1.3 trillion dollars, and US debt has crossed the 40 trillion dollar threshold; Trump argues that a strong economy can cover the payment.
Stars at the Milky Way's core lost their companions to tidal shear from Sagittarius A*
Why the stars on the innermost orbits around the Milky Way's central black hole travel alone has been an open question. Kinematic surveys and simulations now point to the Hills mechanism: a double star that strays within milliparsec distances of Sagittarius A* comes apart, one member flung outward while the other is trapped on a path stretched far from a circle. The survivors are the fast-moving S-cluster stars mapped around the galactic centre.
Supermarkets introduce cheaper fish alternatives amid 'skimpflation' warnings
UK supermarkets are quietly replacing traditional tinned mackerel with jack mackerel, a more affordable and less nutrient-dense fish. Consumer advocates highlight the substitution as a textbook case of 'skimpflation,' where retailers downgrade product quality to absorb rising supply costs.
SVT exit poll puts the centre-left bloc ahead as Sweden counts the votes
Voting closed in Sweden and the first numbers arrived within minutes: the exit poll of public broadcaster SVT gave the centre-left opposition 51.3 percent against 46.8 percent for the right-wing bloc, and an election-day survey by the television channel TV4 pointed the same way. Counting is under way and the first official figures are expected within hours. Swedish exit polls have misfired before, most recently in 2022, when a projected centre-left win became a right-wing government.
Sweden election will decide whether the far right enters cabinet
About 8 million Swedish voters went to the polls to determine the composition of the 349-seat Riksdag. The contest pits Magdalena Andersson's centre-left bloc against Prime Minister Ulf Kristersson's right-wing alliance. A late rise by the Sweden Democrats has narrowed the race, while Kristersson says the far-right party could enter cabinet if the right secures a majority.